NeoPharm Co., Ltd.(KR:092730)
â‚©21,450.00-150.00 (-0.69%)
KR:092730
NeoPharm Co., Ltd. financials statements
â‚©21,450.00
At close:-150.00 (-0.69%)
Want to see KR:092730 full AI Analyst Report?
NeoPharm Co., Ltd. (092730) Ratios
NeoPharm Co., Ltd. Ratios
KR:092730's free cash flow for Q1 2026 was ₩4.61B. For the 2026 fiscal year, KR:092730's free cash flow was decreased by ₩-69.08M and operating cash flow was ₩4.68B. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 8.40 | 10.12 | 7.63 | 9.99 | 9.39 |
| Quick Ratio | 7.65 | 9.28 | 7.06 | 9.33 | 8.77 |
| Cash Ratio | 1.28 | 1.21 | 0.67 | 0.83 | 0.54 |
| Solvency Ratio | 1.24 | 1.68 | 1.42 | 1.42 | 1.47 |
| Operating Cash Flow Ratio | 1.35 | 1.23 | 1.32 | 1.38 | 1.68 |
| Short-Term Operating Cash Flow Coverage | 26.60 | 37.23 | 1315.99 | 977.11 | 1125.36 |
| Net Current Asset Value | â‚© 151.54B | â‚© 137.49B | â‚© 117.07B | â‚© 118.13B | â‚© 108.38B |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| Debt-to-Equity Ratio | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| Debt-to-Capital Ratio | 0.01 | 0.00 | 0.01 | 0.00 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.13 | 1.09 | 1.11 | 1.09 | 1.10 |
| Debt Service Coverage Ratio | 24.78 | 48.41 | 637.26 | 680.02 | 333.52 |
| Interest Coverage Ratio | 729.87 | 604.53 | 1186.85 | 2424.38 | 583.27 |
| Debt to Market Cap | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 124.96 | 42.85 | 139.04 | 53.83 | 76.37 |
| Net Debt to EBITDA | -0.78 | -0.53 | -0.35 | -0.42 | -0.26 |
| Profitability Margins | |||||
| Gross Profit Margin | 64.09% | 62.20% | 67.33% | 68.66% | 70.95% |
| EBIT Margin | 21.77% | 25.42% | 30.27% | 27.44% | 27.15% |
| EBITDA Margin | 24.11% | 28.02% | 31.94% | 29.34% | 28.86% |
| Operating Profit Margin | 21.77% | 20.71% | 26.06% | 25.21% | 25.51% |
| Pretax Profit Margin | 24.41% | 25.38% | 30.25% | 27.43% | 27.11% |
| Net Profit Margin | 21.05% | 19.38% | 23.90% | 20.02% | 20.14% |
| Continuous Operations Profit Margin | 21.05% | 19.38% | 23.90% | 20.02% | 20.14% |
| Net Income Per EBT | 86.24% | 76.35% | 79.03% | 73.00% | 74.31% |
| EBT Per EBIT | 112.12% | 122.53% | 116.07% | 108.79% | 106.26% |
| Return on Assets (ROA) | 12.63% | 11.99% | 13.08% | 10.96% | 12.35% |
| Return on Equity (ROE) | 14.24% | 13.04% | 14.51% | 11.97% | 13.59% |
| Return on Capital Employed (ROCE) | 14.44% | 13.90% | 15.83% | 15.08% | 17.19% |
| Return on Invested Capital (ROIC) | 12.39% | 10.56% | 12.46% | 10.97% | 12.73% |
| Return on Tangible Assets | 12.73% | 12.11% | 13.25% | 11.09% | 12.53% |
| Earnings Yield | 15.26% | 12.44% | 23.62% | 22.62% | 18.27% |
| Efficiency Ratios | |||||
| Receivables Turnover | 9.19 | 9.33 | 9.13 | 11.09 | 10.93 |
| Payables Turnover | 6.20 | 8.94 | 4.93 | 7.20 | 5.88 |
| Inventory Turnover | 3.05 | 3.55 | 3.11 | 3.05 | 3.20 |
| Fixed Asset Turnover | 4.38 | 4.00 | 3.32 | 9.10 | 9.03 |
| Asset Turnover | 0.60 | 0.62 | 0.55 | 0.55 | 0.61 |
| Working Capital Turnover Ratio | 0.90 | 0.93 | 0.83 | 0.75 | 0.85 |
| Cash Conversion Cycle | 100.62 | 101.17 | 83.24 | 102.00 | 85.21 |
| Days of Sales Outstanding | 39.73 | 39.14 | 39.97 | 32.90 | 33.40 |
| Days of Inventory Outstanding | 119.77 | 102.84 | 117.31 | 119.81 | 113.93 |
| Days of Payables Outstanding | 58.88 | 40.81 | 74.05 | 50.71 | 62.11 |
| Operating Cycle | 159.50 | 141.98 | 157.29 | 152.71 | 147.33 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | 1816.36 | 1191.15 | 2976.68 | 2322.02 | 2772.53 |
| Free Cash Flow Per Share | 1740.62 | 994.41 | 311.55 | 2218.91 | 2711.39 |
| Dividend Paid and CapEx Coverage Ratio | 2.69 | 2.08 | 0.88 | 2.89 | 3.90 |
| Capital Expenditure Coverage Ratio | 23.98 | 6.05 | 1.12 | 22.52 | 45.35 |
| Operating Cash Flow Coverage Ratio | 14.83 | 29.60 | 21.84 | 44.06 | 38.80 |
| Operating Cash Flow to Sales Ratio | 0.21 | 0.16 | 0.24 | 0.21 | 0.25 |
| Free Cash Flow Yield | 14.93% | 8.39% | 2.48% | 23.05% | 21.87% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | 6.55 | 8.04 | 4.23 | 4.42 | 5.47 |
| Price-to-Sales (P/S) Ratio | 1.38 | 1.56 | 1.01 | 0.89 | 1.10 |
| Price-to-Book (P/B) Ratio | 0.93 | 1.05 | 0.61 | 0.53 | 0.74 |
| Price-to-Free Cash Flow (P/FCF) Ratio | 6.70 | 11.92 | 40.36 | 4.34 | 4.57 |
| Price-to-Operating Cash Flow Ratio | 6.42 | 9.95 | 4.22 | 4.15 | 4.47 |
| Price-to-Earnings Growth (PEG) Ratio | 0.32 | -11.43 | 0.12 | -1.14 | -2.39 |
| Enterprise Value Multiple | 4.94 | 5.03 | 2.82 | 2.60 | 3.57 |
| Enterprise Value | 157.46B | 167.74B | 87.46B | 64.81B | 90.48B |
| EV to EBITDA | 4.94 | 5.03 | 2.82 | 2.60 | 3.57 |
| EV to Sales | 1.19 | 1.41 | 0.90 | 0.76 | 1.03 |
| EV to Free Cash Flow | 5.78 | 10.78 | 35.92 | 3.73 | 4.27 |
| EV to Operating Cash Flow | 5.54 | 9.00 | 3.76 | 3.57 | 4.17 |
| Tangible Book Value Per Share | 12377.31 | 11184.31 | 20190.54 | 17954.78 | 16400.23 |
| Shareholders’ Equity Per Share | 12490.02 | 11309.05 | 20476.77 | 18183.20 | 16663.03 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.14 | 0.24 | 0.21 | 0.27 | 0.26 |
| Revenue Per Share | 8451.13 | 7609.09 | 12425.45 | 10872.41 | 11244.34 |
| Net Income Per Share | 1778.84 | 1474.63 | 2970.29 | 2177.09 | 2265.12 |
| Tax Burden | 0.86 | 0.76 | 0.79 | 0.73 | 0.74 |
| Interest Burden | 1.12 | 1.00 | 1.00 | 1.00 | 1.00 |
| Research & Development to Revenue | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 |
| SG&A to Revenue | 0.40 | 0.28 | 0.26 | 0.27 | 0.31 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 1.02 | 0.81 | 1.00 | 1.07 | 1.22 |
Currency in KRW

